PRESS RELEASE | Basel, Switzerland, November 10, 2022

Versameb Chief Executive Officer to Present at LSX Inv€$tival Showcase Conference

Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s proprietary mRNA engineering technology platform, VERSagile, at the LSX Inv€$tival Showcase Conference taking place on 14 November 2022 at Old Billingsgate in London, UK.

The Inv€$tival Showcase Conference is focused on connecting life science and healthcare companies with investors and partners to provide a networking opportunity for early, growth-stage and public Biotech, Medtech, Digital Health and Women’s Health companies. The Conference offers headliner and stage speakers plus the opportunity to deliver Company news and deal flow through various sessions profiling each Company with an active and curated audience of investors and strategics.

Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment of Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.

Details of Versameb’s presentation are as follows:

LSX Inv€$tival Showcase Conference
Date: 14 November 2022, Old Billingsgate, London, UK
Presentation by: Klaas Zuideveld
Session: “Biotech Growth Stage – Pre-Series B”
Time: 11.30-11.45 GMT

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to have the opportunity to discuss the positive progress that Versameb has achieved over the past year as we advance our proprietary platform VERSagile to provide treatments to patients suffering with Stress Urinary Incontinence (SUI) and solid tumors. We look forward to an exciting 2023 of key important Company milestones as we further advance our pioneering next generation RNA therapeutics.”

If you would like to meet with the Versameb team at the above event, please contact us using the details provided below. For more information, please visit us at

Contact for media enquiries:

Dr Klaas Zuideveld, CEO

Optimum Strategic Communications
Mary Clark, Charlotte Hepburn-Scott, Zoe Bolt
Tel: +44 (0)20 3882 9621